Sitryx Therapeutics Ltd. has disclosed 2-methylene-4-oxo-butanoic acid derivative compounds acting as nuclear factor erythroid 2-related factor 2 (NFE2-related factor 2; NFE2L2; NRF2) activators reported to be useful for the treatment of inflammatory disorders.